Clinical trial
Rituximab and Combination Chemotherapy in Treating Older Patients With Diffuse…
NCT00101010 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00101010 |
|---|---|
| Title | Rituximab and Combination Chemotherapy in Treating Older Patients With Diffuse Large B-Cell Lymphoma |
| Official title | A Phase II Study Of Rituximab-CHOP With Pegylated Liposomal Doxorubicin In Patients Older Than 60 Years Of Age With Untreated Aggressive B-Cell Non-Hodgkin's Lymphoma |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH Ortho Biotech, Inc. Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Biological, Drug |
| Interventions | Filgrastim, Pegfilgrastim, Rituximab, Cyclophosphamide, Pegylated liposomal doxorubicin hydrochloride, Prednisone, Vincristine Sulfate |
| Enrollment | 80 |
| Start date | Sep 1, 2005 |
| Primary completion | Sep 1, 2014 |
| Completion | Sep 1, 2014 |
| First posted | Jan 10, 2005 |
| Last update posted | Oct 19, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: